Fibrocell Sciences: Corporate Presentation (Fibrocell Science) - Mar 6, 2016 - "Positive Phase I clinical trial results published in peer-reviewed journal"; "Injection of azficel-T into scarred cord lamina propria layer was found to be safe and well-tolerated in trial (n=5): All patients completed the trial, No serious adverse events reported"; "Positive trend of sustained improvement: Sustained improvement from month 3 through month 12 was noted in a majority of patients in the mucosal wave grade assessment, voice handicap index and patient-assessed voice quality, Primary endpoint data summary (n=5)"
P1 data • Fibrosis
|